Related Experiment Video
Updated: Sep 5, 2025
10:01
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
7.0K
Immunotherapy in NSCLC Patients with Brain Metastases
Silvia Buriolla1, Giacomo Pelizzari2, Carla Corvaja1
1Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.
International Journal of Molecular Sciences
|July 9, 2022
Summary
Immune checkpoint inhibitors show promise for non-small cell lung cancer brain metastases. Further research is needed to establish optimal treatment strategies combining ICIs with radiotherapy for improved intracranial control.
Area of Science:
- Oncology
- Neurology
- Immunotherapy
Background:
- Brain metastases (BMs) affect approximately 40% of non-small cell lung cancer (NSCLC) patients, leading to significant morbidity and mortality.
- Managing BMs in NSCLC presents a clinical challenge, necessitating a multidisciplinary approach for effective intracranial disease control.
- Immune checkpoint inhibitors (ICIs) have transformed advanced NSCLC treatment, but patients with BMs are often underrepresented in clinical trials.
Purpose of the Study:
- To review the current clinical evidence on the intracranial activity of ICIs in NSCLC patients with BMs.
- To identify the primary challenges in integrating ICIs into the treatment protocols for NSCLC patients who have developed BMs.
- To evaluate the safety and efficacy of combining ICIs with radiotherapy versus other treatment modalities.
Main Methods:
- Systematic review of published clinical trials and studies.
- Analysis of data on ICI efficacy and safety in patients with NSCLC and BMs.
- Comparative assessment of combination therapies (ICIs + radiotherapy) versus monotherapy or sequential treatments.
Main Results:
- Evidence suggests potential intracranial activity of ICIs in NSCLC patients with BMs.
- Limited data exists from randomized trials, highlighting the underrepresentation of this patient group.
- The optimal combination and sequencing of ICIs and radiotherapy require further investigation.
Conclusions:
- ICIs represent a significant advancement in NSCLC treatment, with emerging evidence for their use in BMs.
- Further research, including well-designed clinical trials, is crucial to define the role of ICIs and combination therapies for NSCLC patients with BMs.
- Optimizing treatment strategies is essential to improve intracranial disease control and patient outcomes.
